SCHEMBL319755

SCHEMBL319755

COC(=O)c1ccc(F)c(-c2c(F)ccc(C(=O)N(C)C)c2F)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 3/20 0.37
MAPT P10636 1/20 0.34
PIM1 P11309 10/20 0.34
PIM3 Q86V86 9/20 0.33
PIM2 Q9P1W9 9/20 0.33
NPC1 O15118 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
MAPK1 P28482 1/20 0.33
KDM4A O75164 1/20 0.32
NUDT1 P36639 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE1C Q14123 1/20 0.32
PDE3A Q14432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318937 0.86 KDM4A (0.39) CTSAPIM1PIM3PIM2SMN1; SMN2
SCHEMBL319082 0.84 GAA (0.38) MAPTPIM1PIM3PIM2NPC1
SCHEMBL319437 0.81 AR (0.37) CTSAMAPTPIM1PIM3PIM2
SCHEMBL1711596 0.80 PIM1 (0.44) MAPTPIM1PIM3PIM2MAPK1
SCHEMBL320431 0.79 MAPT (0.37) MAPTPIM1PIM3PIM2MAPK1
SCHEMBL29599827 0.79 PIM2 (0.46) CTSAMAPTPIM1PIM3PIM2
SCHEMBL15872950 0.79 PIM2 (0.46) CTSAMAPTPIM1PIM3PIM2
SCHEMBL29600679 0.78 MAPT (0.47) MAPTPIM1PIM3PIM2NPC1
SCHEMBL15872828 0.78 MAPT (0.47) MAPTPIM1PIM3PIM2NPC1
SCHEMBL318869 0.77 ERN1 (0.40) MAPTPIM1PIM3PIM2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590968-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS Novartis AG (CH) 2013-05-15 EP disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B CTSA 3138/4885MAPT 2904/4885PIM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.